OFIX

Orthofix Medical Inc. (OFIX) Economic Moat Analysis (2026)

Invetso Score: 3.2/10 — Weak · Last Updated: 2026-08-01

Overall Score

Pricing Power

Gross margin remains high at 69.6%, indicating some pricing power in the product mix.

However, negative net margin (-7.4%) and negative EBIT margin (-4.6%) show that pricing power is not yet translating into durable profitability.

Scale Efficiency

Asset turnover is solid at 0.95x and fixed asset turnover is 6.37x, suggesting decent operating efficiency.

But the operating cycle is long at 325 days and cash conversion cycle is 234 days, which points to weak working-capital efficiency.

Switching Costs

There is no clear evidence of strong switching costs in the current financial profile.

Negative returns on capital and weak earnings quality suggest customers can likely move without meaningful friction.

Intangible Assets

Gross margin near 70% suggests some brand or product differentiation.

Still, the company’s negative profitability and low returns on tangible assets do not support a strong intangible-asset moat.

Network Effects

No evidence of network effects is visible in the financial data.

The business appears to compete on product and execution rather than on a self-reinforcing network.

Cost Advantage

Price-to-sales of 0.50x and EV/sales of 0.66x imply the market is not assigning a premium for a durable cost advantage.

Negative free cash flow and weak operating margins also argue against a clear structural cost edge.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Orthofix Medical Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →